RELAXERA Pharmazeutische GmbH & Co. KG (Allemagne)
Inventeur(s)
Dschietzig, Thomas Bernd
Abrégé
Human relaxin-2 as active ingredient in a pharmaceutical composition for treating a subject exhibiting cachexia syndrome or cardiac wasting or cardiac decompensation. The application also describes methods of treating cachexia, cardiac wasting and patients exhibiting clinical signs of suffering from cardiac decompensation. Further described is a method of using a patch pump for subcutaneous or intravenous infusion of relaxin or human relaxin-2.
RELAXERA PHARMAZEUTISCHE GMBH & CO. KG (Allemagne)
Inventeur(s)
Dschietzig, Thomas Bernd
Benedum, Ulrich M.E.
Abrégé
Relaxera Pharmazeutische GmbH & Co.KG 36 IDK00257PC 20-Nov-23 SUMMARY. A pharmaceutical composition for daily (q.d.) or twice daily (b.i.d.) subcutaneous injection of a bolus of human relaxin-2 or a complex of relaxin-2 and zinc for a period of at least one week, preferably three to twelve months, and injection pens for treating heart failure with preserved ejection fraction, atrial fibrillation, a patient suffering from diabetes and heart failure with preserved ejection fraction, and/or atrial fibrillation; for producing the protective effects of synthetic human relaxin-2 associated with ischemic heart disease, including the reduction of inflammatory leukocyte and platelet responses, inhibition of the release of proinflammatory and arrhythmogenic mediators by leukocytes and mast cells and other harmful substances generated by inflammation, oxidative stress, and necrosis, for use as a broad-spectrum replacement of glucocorticoids, mineralocorticoids, corticosteroids and their analogues in the treatment of tissue and endothelial injury without inducing gluconeogenesis and cushingoid adverse effects; for supporting the repair of tissue and endothelial injuries by promoting immunosuppressive regulatory T cells (Treg), particularly, in autoimmune pathologies and organ transplantation. Figure 4D
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 47/52 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé inorganique, p. ex. un ion inorganique complexé avec l’ingrédient actif
3.
IMMUNOSUPPRESSIVE MEDICAMENT AND METHOD OF TREATMENT
RELAXERA PHARMAZEUTISCHE GESELLSCHAFT MBH & CO. KG (Allemagne)
Inventeur(s)
Dschietzig, Thomas Bernd
Abrégé
Relaxin-2 for use as a broad-spectrum substitute of glucocorticoids, mineralocorticoids, corticosteroids and their analogues for treating tissue and endothelial injuries without incurring inducing gluconeogenesis, Cushing's syndrome and cushingoid adverse effects. Medicament and treatment for supporting the repair of tissue and endothelial injuries by a promotion of immune suppressive regulatory T cells (Treg), particularly, in case of autoimmune pathologies and organ transplantation.
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 19/06 - Agents antigoutte, p. ex. agents antihyperuricémiants ou uricosuriques
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
RELAXERA PHARMAZEUTISCHE GMBH & CO. KG (Allemagne)
Inventeur(s)
Dschietzig, Thomas Bernd
Abrégé
Human relaxin-2 as active ingredient in a pharmaceutical composition for treating a subject suffering from cachexia syndrome or cardiac wasting or suspected of being at risk of suffering from cardiac wasting or cardiac decompensation is described. Also described are methods of diagnosis of cachexia and cardiac wasting and patients suspected of being at risk of suffering from cardiac decompensation. Further described is a patch pump for sc. or iv infusion of relaxin or human relaxin-2.
RELAXERA PHARMAZEUTISCHE GMBH & CO. KG (Allemagne)
Inventeur(s)
Dschietzig, Thomas Bernd
Abrégé
Human relaxin-2 as active ingredient in a pharmaceutical composition for treating a subject suffering from cachexia syndrome or cardiac wasting or suspected of being at risk of suffering from cardiac wasting or cardiac decompensation. The application also described methods of diagnosis of cachexia and cardiac wasting and patients suspected of being at risk of suffering from cardiac decompensation. Further described is a patch pump for sc. or iv infusion of relaxin or human relaxin-2.
Relaxera Pharmazeutische Gesellschaft mbH & Co. KG (Allemagne)
Inventeur(s)
Dschietzig, Thomas B.
Abrégé
A pharmaceutical composition for treatment of persons afflicted of heart failure with preserved ejection fraction (HFPEF), diastolic heart failure (DHF) or diastolic dysfunction (DF), the composition comprising a therapeutically effective amount of a compound capable of specific binding to the relaxin receptor (RXFP1) present on fibroblasts, fibromyoblasts, endothelial cells, endocardial cells, and cardiomyocytes in the cardiac muscle to increase the heart's stroke volume at lower end-diastolic pressure.
Relaxera Pharmazeutische Gesellschaft mbH & Co. KG (Allemagne)
Inventeur(s)
Dschietzig, Thomas B.
Abrégé
A pharmaceutical composition for treatment of persons afflicted of heart failure with preserved ejection fraction (HFPEF), diastolic heart failure (DHF) or diastolic dysfunction (DF), the composition comprising a therapeutically effective amount of a compound capable of specific binding to the relaxin receptor (RXFP1) present on fibroblasts, fibromyoblasts, endothelial cells, endocardial cells, and cardiomyocytes in the cardiac muscle to increase the heart's stroke volume at lower end-diastolic pressure.
A61P 1/04 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des ulcères, des gastrites ou des œsophagites par reflux, p. ex. antiacides, antisécrétoires, protecteurs de la muqueuse
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
RELAXERA PHARMAZEUTISCHE GESELLSCHAFT MBH & CO. KG (Allemagne)
Inventeur(s)
Dschietzig, Thomas
Abrégé
A pharmaceutical composition for treatment of persons afflicted of heart failure with preserved ejection fraction (HFPEF), diastolic heart failure (DHF) or diastolic dysfunction (DF), the composition comprising a therapeutically effective amount of a compound capable of specific binding to the relaxin receptor (RXFPI) present on fibroblasts, fibromyoblasts, endothelial cells, eudocardial cells, and cardiomyoeytes in the cardiac muscle to increase the heart's stroke volume at lower end-diastolic pressure.
brevets
